In November 2019, we made two pieces on detransitioning – for @BBCNewsnight and @BBCfileon4. They featured ‘Debbie, ’ who began transitioning to a man at the age of 44.
She had been given testosterone at her first appointment, and completed a full surgical transition over a number of years. She changed her name legally to Lee. When we spoke, Debbie had taken the decision, after 17 years, to stop her testosterone injections.
She wanted to detransition and posed the question, “how the hell do I go back to being the Debbie that I was?” Speaking then, Debbie was unsure about what the long-term implications may be for her and talked about the possibility of reversing some of her surgery.
She was being seen by one of the NHS’s Gender Identity Clinics, but said they were not sure how to help.
Today, Debbie, now preferring to be called Lee again, is pictured along with four more detransitioning or detransitioned women in @BareReality ‘s piece for the Sunday Times
Lee is quoted as saying, “I thought I would detransition, but I’ve decided I can’t physically do it. My body can’t take it. I’m not sure I’d survive all the surgeries. I’d be battling my body for the rest of my life. I have to accept my body the way it is now.”
“On the outside people see a little bloke. Inside I’m a traumatised little girl. But I’m more accepting of myself for the first time ever.”
I hope they can find happiness and peace.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The Amos review represents a missed opportunity for real change & sadly tells us nothing new. Families are right to feel disappointed. Their voices are surprisingly lacking. Their questions left unanswered. My reflections for @NewStatesman... (🧵) newstatesman.com/politics/healt…
It is staggering that from the thousands of women who provided testimony to the national maternity investigation, the final reoort contains not one case of a mother being left physically injured by birth.
The most damning reflections are arguably contained in the small, light-touch reports of the 12 maternity units reviewed. But these also raise plenty of questions. Amos says she is worried about ongoing patient safety at both Sandwell & West Birmingham NHS Trust and Yeovil District hospital. But what will happen now? There is no call to action.
NEW: While the whole world is focused is on who will be our next Prime Minister, it’s quietly confirmed that the NHS-backed Pathways puberty blocker trial has bee reapproved, with some small changes. A minimum age of entry of 11 for girls and 12 for boys… gov.uk/government/new…
The KCL trial team say “There are no major changes to the design or conduct of PATHWAYS TRIAL as a result of our discussions with the MHRA. We have, however, made some modifications to the clinical trial protocol and patient information.”
This has been modified to include:
•Further details about the potential risk of impact of puberty suppression on bone mineral density
•Greater information about fertility counselling and preservation options for birth-registered females and males, with review discussions with young people at 12 and 24 months after the young person has joined the clinical trial.
🧵In July 2024 I broke news that the BMA was planning to vote on a motion to "disavow" the Cass Review & work with others to oppose implementation of its recommendations. Nearly two years' later, the union has officially dropped its opposition, after conducting its own review.
This followed backlash from members, including resignations. Today, 18 months after it was due, the BMA review's lead author told The Times, Cass had been “vindicated in the way she approached the data” & the union did not oppose a single recommendation
However, division endures. BMJ reports that while the report concluded evidence base for puberty suppression & hormones is "limited and uncertain", the BMA remains critical of Gov's response to Cass, e.g. the decision to ban puberty blockers for under 18s. bmj.com/content/393/bm…
(🧵) NEW: Today’s news that NHS England has paused new prescriptions of cross-sex hormones for under 18s a) seems a bigger deal than being suggested, b) raises several questions, c) has potentially significant consequences for any forthcoming trial of puberty blockers...
England has - for a period at least - ended the medical transition of children on the NHS. This puts a stop to 20+ years of practice. (The former Tavistock Gender Identity Development Service [GIDS] referred 16 year olds for puberty blockers from around the year 2000.)
The precise trigger for the pause seems unclear. What is the “in-depth review of all available clinical evidence” referred to by NHSE in their statement? I have asked NHSE. NHSE's statement says it was triggered by Dr Hilary Cass’s 2024 major report into children's gender care...
🚨BREAKING: NHS-backed puberty blocker trial PAUSED as regulator raises safety concerns. The Medicines & Healthcare products Regulatory Agency (MHRA) has requested the King’s College trial team amend study protocol, to better reflect risks to children 🧵 assets.publishing.service.gov.uk/media/6998b06d…
Trial team are asked to increase the minimum age of participants to 14 because of fertility concerns.
MHRA explicitly recognises "sterilising effect of puberty blockers followed by cross sex hormones and that gamete retrieval to preserve fertility is not possible at the stage when puberty blockers are given (Tanner stage 2) as neither sperm nor ova have matured."
NEW: I’ve taken a deep dive into the new puberty blockers trial, exploring how we got here, what it will and won’t answers, with a sprinkling of new revelations too.
With contributions from Hilary Cass, trial team members (past & present) and MPs
A former member of the trial told me, “the early planning meetings were unlike any other clinical trial I’ve encountered. We could easily list all the potential harms to monitor and how to test for them, but we didn’t have a clear rationale for giving the drug in the first place”
I can also reveal:
- Close to one in eight children being seen at the London gender hub have disclosed self-medicating with hormones
- NHSE hasn’t started the data linkage study of former Gids patients & has not got the required ethical and regulatory permissions to do so AND…